NeuroOne Medical Technologies Corporation will conduct a virtual roadshow webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time to discuss business operations, recent FDA clearance, and corporate updates. The medical technology company, which trades on Nasdaq under the symbol NMTC, focuses on improving surgical care options and outcomes for patients suffering from neurological disorders.
The webinar represents an important opportunity for investors and stakeholders to understand the implications of NeuroOne's recent regulatory progress. FDA clearance for medical devices represents a critical milestone that can significantly impact patient access to new treatments and the company's commercial trajectory. For patients suffering from conditions like epilepsy, Parkinson's disease, and chronic pain, such developments can signal potential new treatment options becoming available in the healthcare market.
NeuroOne's technology portfolio includes minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation solutions. These technologies target neurological conditions including dystonia, essential tremors, and chronic pain due to failed back surgeries. The company's approach aims to improve patient outcomes while potentially reducing procedural costs, addressing two significant challenges in neurological care.
The virtual format allows broad participation from the investment community and other stakeholders. Participants can access the webcast through the provided NMTC Virtual Webinar Link or by dialing 888-506-0062 within the United States or 973-528-0011 internationally using access code 619723. The company recommends joining at least five minutes before the scheduled start time to ensure timely participation.
Following the presentation, management will conduct a question-and-answer session, providing additional context about the company's strategic direction and recent developments. A playback of the call will be available through October 21, 2025, accessible by calling 877-481-4010 within the United States or 919-882-2331 internationally using replay passcode 53045.
The neurological disorder treatment market represents a significant healthcare segment with substantial unmet medical needs. Advances in medical technology for conditions such as epilepsy and Parkinson's disease can have profound implications for patient quality of life and healthcare system efficiency. NeuroOne's potential expansion into additional applications including depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence suggests broader relevance across multiple therapeutic areas.
For more information about the company's technology and development programs, interested parties can visit nmtc1.com. The investor relations contact for NeuroOne is MZ Group - MZ North America, reachable at NMTC@mzgroup.us.
